Opinion

Video

Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

Key Takeaways

  • FcRn inhibitors have distinct dosing and administration protocols, necessitating careful consideration by clinicians for optimal therapeutic outcomes.
  • Adherence to specific dosing guidelines is crucial to maximize efficacy and minimize adverse effects in patients receiving FcRn inhibitors.
SHOW MORE

Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.

Video content above is prompted by the following:

  • Approved and investigational FcRn inhibitors have different dosing/administration regimens.
    • Do you follow these dosing regimens in your patients?
Related Videos
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.